AARON N ROCKOFF
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism ORANGE, CA NPI 1902104839
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism CA Lilly USA, LLC All categories
General Payments — all program years on this page
$12,558.59
- Category: General Payments
- Program years: PY2018–2024
- Record count: 786
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,486.24 across 155 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,486.24 | 155 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $376.05 | 28 |
| Amgen Inc. | $230.76 | 16 |
| ABBVIE INC. | $202.57 | 12 |
| Novo Nordisk AS | $197.49 | 11 |
| Antares Pharma, Inc. | $157.77 | 28 |
| SANOFI-AVENTIS U.S. LLC | $131.25 | 7 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $101.64 | 4 |
| RECORDATI_RARE_DISEASES_INC. | $98.38 | 4 |
| Radius Health, Inc. | $96.43 | 4 |
| DEXCOM, INC. | $83.25 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $78.29 | 4 |
| Abbott Laboratories | $75.31 | 3 |
| Insulet Corporation | $66.18 | 3 |
| CeQur Corporation | $62.42 | 1 |
| Alexion Pharmaceuticals, Inc. | $54.18 | 2 |
| Corcept Therapeutics | $51.46 | 2 |
| TOLMAR, INC. | $44.93 | 3 |
| Tandem Diabetes Care, Inc. | $42.71 | 2 |
| MannKind Corporation | $40.89 | 2 |
| Embecta Corp. | $37.86 | 2 |
| Alvogen Inc | $33.34 | 2 |
| Amphastar Pharmaceuticals, Inc. | $30.85 | 2 |
| Neurocrine BioSciences, Inc. | $28.02 | 1 |
| Kyowa Kirin, Inc. | $24.77 | 1 |
| EISAI INC. | $24.21 | 1 |
| Medtronic, Inc. | $22.29 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $21.33 | 1 |
| Ascendis Pharma Inc | $20.46 | 1 |
| Xeris Pharmaceuticals, Inc. | $19.70 | 1 |
| BETA BIONICS, INC. | $15.91 | 1 |
| Madrigal Pharmaceuticals | $15.54 | 1 |
By program year
Records — PY2024 (155)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.